Appropriate diabetes self-management is essential to achieving optimal clinical outcomes. The Patient Activation Measure (PAM) is a validated, 100-item questionnaire that assesses patient activation (scored: 0=low, 100=high) and reveals four levels of activation relevant to diabetes self-management: Level 1 - disengaged and overwhelmed; Level 2 - becoming aware but still struggling; Level 3 - taking action and gaining control; and Level 4 - maintaining behaviors and pushing forward. This 12-month, observational, self-controlled multi-site study combined retrospective (6 months pre-baseline) and prospective (6 months post-baseline) to assess the impact of the Diabetes Health Partnership (DHP) program, a telephonic coaching program, on patient activation among 57 suboptimally controlled at baseline (8.4±1.1% A1C). Mean PAM total scores increased from 61.8±12.1 at baseline to 71.3±12.7 at study endpoint (p<0.0001). The downward shift in Level 1 and upward shift in Level 4 were most notable. (Figure 1) Significant increases in participant confidence in managing their diabetes (p<0.0001) and in having a clear plan for self-management (p=0.0004) were observed. Participation in the DHP program was associated with increased activation and greater confidence in participants’ ability to manage their diabetes.
A. Buskirk: Employee; Self; Roche Diabetes Care. W.C. Biggs: Consultant; Self; Roche Diabetes Care. Research Support; Self; Dexcom, Inc., Gan & Lee Pharmaceuticals, Mylan, Novo Nordisk A/S, Sanofi US. L. Borsa: None. M.R. Lyden: None. C. Parkin: Consultant; Self; Abbott, CeQur Corporation, Dexcom, Inc., DreaMed Diabetes, Novo Nordisk Inc., Onduo, Roche Diabetes Care, Valeritas, Inc.
